Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Boehringer Ingelheim

Status: Completed

Conditions: Geographic Atrophy

Study type: Observational

Funder types: Industry

Identifiers

NCT05891275

1484-0014

Details and patient eligibility

About

To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).

Enrollment: 68,563 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients ≥50 years, with a GA diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023).

Exclusion criteria

• Patients without the information of laterality will be excluded.

Trial design

68,563 participants in 1 patient group

Patients with a Geographic Atrophy diagnosis

Description:

Patients diagnosed with geographic atrophy (GA) in at least one eye, at least 50 years old with information on laterality, and registered in the Vestrum health database between January 2015 and April 2023.